CSI Market
Sign In | Register

X4 Pharmaceuticals Inc (XFOR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access XFOR Annual Cash Flow →
The data below summarizes X4 Pharmaceuticals Inc's cash flow activity from Mar 31 2025 to Mar 31 2026, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-20.24
Depreciation & amortization0.22
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.16
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation2.41
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Non Cash Interest Expense0.23
Adjustment Of Non Cash Rent Expense-
Derivative Gain Loss On Derivative Net-
Increase Decrease In Grant And Incentive Receivables-
Gain Loss On Preferred Stock Repurchase Liability-
Increase Decrease In Lease Liabilities-0.26
Change In Fair Value Of Convertible Preferred Stock Warrant Liability-0.08
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.54
Increase (Decrease) in Accounts Payable-0.62
Increase (Decrease) in Accrued Liabilities-1.55
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.78
Other Working Capital0.00
Other Noncash Income (Expense)-0.11
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.32
Discontinued operations0.00
Net Cash flow from Operating Activities-19.60
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities19.25
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities19.25
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments Of Issuance Costs Of Convertible Promissory Notes-
Proceeds From Issuance Of Loans Payable-
Payments Of Issuance Costs Of Redeemable Convertible Preferred Stock-
Sale Of Common Stock Pre Funded Warrants And Class A Warrants Net Of Issuance Costs-
Proceeds From Exercise Of Stock Options And Warrants-
Proceeds From Issuance Or Sale Of Equity Net Of Issuance Costs-
Proceeds From Borrowings Under Loan And Security Agreements Net Of Issuance Costs-
Issuance Costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow-0.02
Discontinued operations0.00
Free Cash Flow-19.60
Total Cash Flow-0.37
4 historic quarters locked

Sign in to unlock the full X4 Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About X4 Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001501697-26-000068

Figures are derived from filed reports and may be restated. Historical data is subject to revision.